TIDMBMK

RNS Number : 7421V

Benchmark Holdings PLC

16 April 2021

16 April 2021

Benchmark Holdings

("Benchmark" or the "Company")

BMK08+CleanTreat Ò Update

Ratification of Maximum Residue Limit under European Law

Significant milestone towards the commercialisation of BMK08 and CleanTreat Ò

Further to the notification made on 10 September 2020, Benchmark Holdings is pleased to announce that the MRL (Maximum Residue Limit) for its novel sea lice treatment BMK08 has now been ratified under European Law. The MRL confirms the safety of Benchmark's sea lice solution for consumers and represents a significant milestone in the regulatory approval process towards the anticipated commercial launch of BMK08 and CleanTreat Ò in Norway. The commercial launch remains subject to the grant of a Marketing Authorisation in Norway.

BMK08 and CleanTreat Ò is a transformational solution addressing the biggest biological challenge in salmon farming. The MRL EU ratification is the culmination of almost a decade of research and development, a rigorous trial programme and substantial capital investment by Benchmark.

   Trond Williksen,   CEO, commented: 

"The ratification of the MRL is a further stepping stone towards commercialisation following the announcement of our first customer agreements for CleanTreat â announced in March.

Sea lice continues to be the biggest biological challenge for salmon producers and Benchmark's novel solution addresses this challenge in a sustainable way both in terms of animal welfare and environmental impact."

Enquiries:

 
Benchmark Holdings plc                     Tel: 020 3696 0630 
Ivonne Cantu, Investor Relations Director 
Rachel Aninakwah, Communications 
 
Numis (Broker and NOMAD)                   Tel: 020 7260 1000 
James Black / Freddie Barnfield / Duncan 
 Monteith 
 
M HP 
Katie Hunt /Alistair de Kare-Silver        Tel: 020 3128 8742 
                                            benchmark@mhpc.com 
 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDDKABNCBKKAQD

(END) Dow Jones Newswires

April 16, 2021 06:00 ET (10:00 GMT)